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Background: The Masimo Pronto-7W calculates hemoglobin (Hb) values using the pulsoximetry technique and a
variety of mathematical algorithms analyzing the pulse waveform. Although this system has demonstrated a high
level of accuracy in average patients, the performance might be altered in special patient populations. Regarding
patients with left ventricular cardiac failure, a rotary blood pump generates a constant, continuous, non-pulsatile
flow to improve effective cardiac output. Due to this alteration in both, blood flow and arterial blood pressure we
hypothesized a reduced accuracy of the Masimo Pronto-7W to detect Hb in patients with left ventricular cardiac
failure. To test our hypothesis, we evaluated the Pronto-7WSpHb system in outpatients after continuous-flow-left
ventricular assist device (cf-LVAD) implantation (HeartMate II, Thoratec).
Methods: 21 cf-LVAD outpatients from the Clinic for Cardiac, Thoracic and Vascular Surgery were investigated
during routine follow up examinations. After venous blood samples were drawn, the Pronto-7W sensor was
attached to one randomly selected finger of one hand. The collected SpHb data were compared with Hb values
measured by our central laboratory. The difference between the methods was determined using Bland – Altman
analysis. The study was registered in the DRKS (DRKS00004415).
Results: In all cf-LVAD patients evaluated, the Pronto-7W successfully detected SpHb values. Using Bland – Altman
analysis, a bias of 0.14 g/dl (95% upper and lower limits of agreement ± 2.76 g/dl) was calculated.
Conclusion: The Pronto-7W overestimated the actual Hb value in cf-LVAD outpatients with the HeartMate II. Due to
this, we conclude that the system is suitable for screening in routine examinations and further analysis can be
performed if needed. However, its use as an emergency tool is questionable because of the increased inaccuracy
when Hb values are critically low.
Keywords: Perioperative care, Circulatory assist devices, Blood transfusion, Emergency, Patient safetyBackground
Performance of pulse oximetry has improved during the
last few years. Indeed, current pulse oximetry devices
have reached a high level of validity and reliability, even
in patients with altered or hampered pulse wave curves
[1]. The development is owed to an increasing number
of wavelengths used for light emitting diodes and im-
proved mathematical algorithms that allow higher stabil-
ity of the signal and validity of the interpretation. Several* Correspondence: gschaelte@ukaachen.de
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reproduction in any medium, provided the ornew analyzing tools, including pulse oximetry based
hemoglobin (SpHb) monitoring, have recently been
established and tested in different clinical settings, such
as acute hemorrhage [2], obstetrics [3], conditions of he-
modilution [4] and on mixed ICU patient populations
[5].
Concomitant to this huge step in pulse oximetry per-
formance, challenges for acute measurements for these
systems have remained, especially in cardiac surgery pa-
tients. Several devices have been introduced to support
cardiac function or to take over the complete left, right
or both cardiac outputs. Implanted devices in patients
suffering from severe cardiac failure are generally classi-
fied into pulsatile or continuous flow (cf) generatingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tems. Higher long-term survival rates at two years are
currently being reported for patients supported by con-
tinuous flow systems [6]. Importantly, adverse events
and the need for device replacement are less frequent in
patients with continuous flow systems, which may favor
their use over pulsatile systems. However, the risk of
bleeding exists in both systems, with the rate of occur-
rence for packed red blood cell transfusions up to 81%
[6].
As a function of design, pulsatile LVAD are more simi-
lar to the normal, physiologic cardiovascular function,
which is mainly characterized by the beating heart with
accelerating and decelerating flow rates. Conversely, cf-
LVAD generate a continuous flow of blood with no de-
tectable changes in flow rate. These devices are compar-
able to the cardiopulmonary bypass with no blood
pressure curve, rather they are characterized by the ab-
sence of systolic and diastolic pressures. Nevertheless, in
many patients some low-grade basal left ventricular
function remains or is regained after device implant-
ation, generating an ‘on top’ pulse wave.
The absence of a pulsatile flow in patients with cf sys-
tems is a challenge for pulse oximetry based Hb
detecting systems and the implemented mathematical al-
gorithms. To test the accuracy of the Pronto 7W system,
we measured SpHb values in 21 cf-LVAD patients with
implanted HeartMate II devices and compared these
values to the Hb measurements taken from venous
blood samples. Due to the convenience, speed and im-
proved performance of pulse-oximetry, it is important to
know whether this device can accurately detect Hb in
patients with cf-LVAD devices. Moreover, given the high
number of bleeding incidents in cf-LVAD patients, ac-
curate SpHb measurements are crucial in emergency
settings. We hypothesized that the accuracy of the
Masimo Pronto-7W system for SpHb measurements may
be reduced in patients with cf-LVAD devices due to the
absence of pulsatile blood flow.
Methods
21 Caucasian patients (13 male, 8 female) from the spe-
cialized outpatient division for assist device patients of
the Clinic for Cardiothoracic and Vascular Surgery of
Aachen University Hospital were investigated. The ethics
committee of the medical faculty of the RWTH Aachen
waived the requirement to obtain informed consent
from patients due to the non-invasive nature of the
study (EK 223/12). Venous blood samples were taken
from the median cubital vein as part of routine follow
up examinations based on the established protocol for
cf-LVAD patients. However, in one patient who was be-
ing treated in the intermediate care unit due to recent
bleeding, the blood sample was obtained from thecentral venous line. After the venous blood sample we
used the Masimo RainbowW SETW Pronto-7TM Puls CO-
Oximeter generating several wavelengths in a range of
500 nm-1300 nm to detect SpHb values besides func-
tional oxygen saturation values (SpO2), pulse rate (PR),
and Perfusion index (PI). The installed software calcu-
lates SpHb values based on the pulse-waveform, the de-
tailed mathematical formulas are not publically available.
The Pronto-7W was set to the mode that allowed a
higher acceptance of unusual pulse wave forms but
linked with a 10% higher standard deviation of differ-
ences, (i.e. 68% of the SpHb values have a lower differ-
ence than 1.1 g/dl to a Hb value, instead of 1 g/dl in the
standard operating mode). The finger clip (medium size)
was placed randomly at one of the three fingers (Dig II,
III, or IV) of one hand. Five attempts were made to ob-
tain the SpHb measurements. If the system could not
calculate a SpHb, the finger clip was replaced anew to
exclude misplacement. Finger nails were free of nail pol-
ish to reduce any potential measurement errors. The
first SpHb value displayed was noted as well as PR,
SpO2 and PI. All blood samples (EDTA) were investi-
gated in the hospital’s central laboratory facility follow-
ing standard clinical procedure. Blood pressure (RR) was
measured manually after the venous blood draw and
pulse oximetry measurements.
Statistical procedures
Mean and standard deviations of SpHb, Hb, PR, PI were
calculated. The difference between SpHb, and Hb values
was analyzed based on the methods published by Bland
and Altman [7]. The limits of agreement were estimated
by calculating the mean difference (bias) and the stand-
ard deviation (SD).
The upper and lower limits were defined as bias ± the
range in which 95% of the differences between the
methods were expected to occur. The confidence inter-
vals for the limits of agreement were defined by the termffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
3SD2=n
p
where n is the sample size. The CI for the
biases were calculated based on the sample size by the
term
ffiffiffiffiffiffiffiffiffiffiffiffiffi
SD2=n
p
. Linear regression analysis was used to
detect dependencies between PI, PR, RR and the relative
differences between SpHb and Hb values. The methods
described above have been used before by our group [8].
All statistical calculations were done using GraphPad
Prism version 5.00 for MacOS, GraphPad Software, San
Diego California USA,) and SPSS 20 (IBM Corporation,
Armonk, New York, USA).
Results
Patients
The Pronto-7W system was able to acquire data in 18 pa-
tients on the first attempt. In one patient, three attempts
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sary to obtain a SpHb value. One patient investigated
was treated for sub-acute bleeding and was recovering in
the intermediate care unit, having received two units of
red packed blood cells two hours before. Patient charac-
teristics are given in Table 1. The patient characteristics
concerning age, BNP levels, PR, systolic RR and PI did
not differ significantly. In four patients no diastolic
blood pressure could be measured. No adverse events
occurred in any of the patients during the study.Differences in Hb and SpHb values
The mean Hb value of the patients was 11.94 g/dl (SD ±
1.71), with a range between 7.5 g/dl and 14 g/dl. TheTable 1 Patient characteristics of the left ventricular
assist device patients investigated
Absolute Male Female
Age (mean±SD) 62.9±10.1 65.77±8.02 57.1±11.90
Systolic blood pressure
(mmHg, mean±SD)
103.3±11.65 104.5±13.16 101.4±9.4
BNP (mean±SD) 1025.05±
874.74
1217.5±
979.53
695.14±
259.52
Pulse rate
(per minute, mean±SD)
68.95±13.12 67.46±14.49 71.71±9.5
Pulse index (mean±SD) 2.63±2.98 3.2±3.42 1.56±1.05
Comorbidities –n (%)
Coronary artery disease 18 (90%) 12 (92%) 6 (86%)
Arterial hypertension 13 (65%) 8 (62%) 5 (71%)
Diabetes 6 (30%) 5 (38%) 1 (14%)
Hyperlipidemia 8 (40%) 6 (46%) 2 (29%)
Renal failure 10 (50%) 8 (62%) 2 (29%)
Stroke 3 (15%) 1 (8%) 2 (29%)
Peripheral vascular disease 7 (35%) 5 (38%) 2 (29%)
Pacer /ICD 7 (35%) 5 (38%) 2 (29%)
Atrial fibrillation 1 (5%) 1 (8%) 0
Valve dysfunction
Aortic valve stenosis 4 (20%) 3 (15%) 1 (14%)
Aortic valve insufficiency 1 (5%)* 1 (8%) 0
Mitral valve insufficiency 2 (10%) 1 (8%) 1 (14%)#
Tricuspidal valve insufficiency 0 0 1 (14%)#
Pulmonary hypertension 8 (40%) 5 (38%) 3 (43%)
Acute hemorrhage 1 (5%) 1 (8%) 0
Chronic hemorrhage 1 (5%) 1 (8%) 0
Chronic obstructive
pulmonary disease
5 (25%) 4 (31%) 1 (14%)
*combined vitium (stenosis and insufficiency) in one patient, # combined
mitral tricuspid insufficiency in one patient. BNP= Brain natriuretic peptide.
Percentages are given between male/female patient population or in between
the sex groups.mean SpHb values as measured by the Masimo Pronto-7W
was 12.08 g/dl (SD ±1.73 g/dl), with a range between
8.8 g/dl and 15.1 g/dl (see Figure 1). The mean differ-
ence (i.e., bias) between the SpHb values measured with
Pronto-7W and the Hb measured in the venous blood
sample was 0.14 g/dl (95% CI: ± 0.31). The upper and
lower limits of agreement were calculated as -2.62 g/dl
and 2.89 g/dl (95% CI: ± 0.55) (Figure 2). Regarding the
relative differences between SpHb and Hb values, the
bias was 1.20% (95% CI: ± 2.8) with upper and lower
limits of agreement ranging between -23.34% and
25.74% (95% CI: ± 4.85), respectively (Figure 2). Linear
regression models calculated from PI, PR and RR values
and the relative differences between SpHb/Hb values re-
vealed no dependency of these parameters to the relative
differences (PI: R2 = 0.001, PR: R2 = 0.032, RR: R2 = 0.01).Discussion
Using Bland – Altman analysis, our study revealed a bias
of 0.14 g/dl (or 1.2%) between the SpHb and Hb values
with limits of agreement between 2.62 g/dl and 2.89 g /dl
(23.3% and 25.74%). We could not detect a correlation be-
tween clinical parameters as PR or RR and SpHb accuracy.
A detailed discussion of the findings follows.
For SpHb measurements, a variety of studies have
been performed to gain insight about the accuracy of
this novel technique in different clinical settings
[2-4,9-11]. The accuracy of SpHb measurements in
stable patients without acute hemorrhage or cardiovas-
cular insufficiency is remarkable [1,5], defining the
Pronto-7W as a tool of standard care procedure. We in-
vestigated the use of this device on a patient subset withFigure 1 Distribution of absolute values of SpHb and Hb values
from the investigated left ventricular assist device patients
including mean and standard deviation.
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Figure 2 Bland-Altman plot for differences between SpHb and Hb values. The upper and lower Limits of agreements (LOA) were calculated
as the bias ± 2 standard deviations.
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measurement of Hb. Given that our subjects lacked pul-
satile blood flow, we expected this to likely influence
both flow and pulse waveform characteristics. Neverthe-
less, in all our patients, the device successfully detected
an Hb value, indicating that the remaining contractions
of the left ventricle generated a sufficient enough pulse
wave that could be analyzed by the implemented algo-
rithm of the Pronto-7W.
Patients
The patients we investigated were all in stable clinical
conditions as indicated by ECG, pulse rate, systolic
blood pressure and hemoglobin values (see Table 1), ex-
cept for one patient that was treated in the intermediate
care unit after an acute hemorrhage. The incidence of is-
chemic cardiac disease was elevated in our patient popu-
lation compared to the patient population described by
Slaughter et al. who reported ischemic heart failure of
66% [6]. Mean Hb values of the patients (11.94 g/dl
(SD ±1.71)) are slightly lower than the normal range for our
laboratory (12-16 g/dl). The one patient suffering from
acute hemorrhage that required surgical intervention
and transfusion had the lowest Hb values (7.5 g/dl), and
remained stable afterwards. We were able to successfully
obtain SpHb values from all 21 patients which is a lower
rate of failure (0.0%) than previous studies who could
not detect a SpHb in <2.5% of a mixed patient population
[12] or 8% of emergency ward patients [13]. Never-
theless, in two of our patients, several attempts had to
be made to successfully obtain values.
Accuracy of the SpHb measurements
Our results with a bias of 0.14 (SD ± 1.41) g/dl regarding
absolute difference are comparable to different clinical
studies that show the same low levels of bias [4,5].
Frasca et al. investigated intensive care patients, found a
bias of 0.0 g/dl [5], while Berkow et al. detected a bias of-0.1 g/dl during spine surgery [2]. Hemodilution in
healthy volunteers did not affect the accuracy with a bias
of -0.15 g/dl [4]. In contrast, much higher biases were
found in more heterogeneously distributed patients
(0.56 g/dl) [12] or in patients with acute hemorrhage (up
to 1.0 g/dl) [14] respectively. In the mode of maximal
sensitivity of healthy volunteers, the manual describes an
SD of ±1.1 g/ dl when values were between 6-18 g/dl.
Our study detected a SD of the bias of ± 1.41, which is
higher. These findings could be interpreted as high or
negligible, depending on the clinical situation. Therefore
we calculated the relative bias (1.2%), underlining the
small variety of SpHb-Hb differences. Even more inter-
esting for the assessment of accuracy besides the bias
are the upper and lower limits agreement, (i.e. the range
in which 95% of the differences between the methods
are expected to occur). In this trial those limits ranged
between -2.62 g/dl and 2.89 g/dl. This range exceeded
the limits given for FDA approval in the user manual
(2 g/dl) and are lower than the findings of Miller in pa-
tients during spine surgery [10], but higher than Berkow
et al. reported in their patient population [2]. Interestingly,
in cardiac surgery patients, Nguyen revealed a wide range
of limits of agreement (between -4.6 g/dl and 2.1 g/dl) [11].
These values were influenced by the software release, as a
consequence we used the latest software update available.
The updated software possibly explains the increased ac-
curacy of our findings. Nguyen et al. concluded that based
on their findings, the SpHb system cannot (yet) be
recommended [11]. This conclusion is shared by Gayat
and colleagues based on the mixed patient population
study with nearly 300 patients [12]. In addition to the abso-
lute values, we calculated the relative values to allow a bet-
ter interpretation and weighting of these differences. The
calculated limits of agreement (LOA; -23.34% and 25.74%)
support the conclusions drawn by the study of Ngyuen and
Gayat: that the Pronto-7W is not recommended for patients
with cf-LVAD in its current state [11,12].
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tients since these are the patients that stand to benefit
the most from a quick and reliable diagnosis. The fol-
lowing example from our own study illustrates the im-
portance of accurate readings in anemic patients. Our
patient that suffered from an acute hemorrhage had a
Hb value of 7.5 g/dl as measured from the venous blood
sample; as such, a transfusion of red packed blood
cells is indicated. The SpHb value obtained from the
Massimo Pronto-7W differed by 17% (8.5 g/dl SpHb).
Importantly, these values are close enough to a “safe”
value, where no transfusion might be considered. Fur-
thermore, the absolute difference between the Pronto-
7W and the measured venous sample (1 g/dl) is still
within the range given by the manufacturer. This situ-
ation clearly emphasizes the dilemma of the utility of the
device at low Hb values. Morey and colleagues [15] cre-
ated a graph consisting of three zones (red, yellow,
green) (see Figure 3), in which the bias of the measure-
ments can result in different clinical decisions, his figure
is based on a publication regarding SpHb device accur-
acy [4]. When values are within the green zone, the bias is
without further therapeutic consequence, the errors lying
in the yellow or red zone may lead to major therapeutic
errors. The authors defined these zones according to the
2006 practice guidelines for transfusion developed by theFigure 3 Error grid analysis, redrawn after [15] using a linear
regression plot between SpHb and Hb values (g/dl). The dotted
lines indicate the 95% prediction bands, in which 95% of the data
points are expected to fall. The graph is consisting of three zones
(red, yellow, green), in which the bias of the measurements results
in different clinical decisions. While in the green zone the bias is
without further therapeutic consequence, the errors lying in the
yellow or red zone may lead to major therapeutic errors.American Society of Anesthesiologists Task Force on Peri-
operative Blood Transfusion and Adjuvant therapies and a
possible deviation of 10% (i.e., 1 g/dl at Hb 10 g/dl). Using
this graph (Figure 3), we conclude that the accuracy of this
device is unacceptable for diagnostic use to base therapeutic
interventions in patients with cf-LVAD implants. However,
given these findings, the Pronto-7W could be an acceptable
and convenient preliminary screening device to identify cf-
LVAD patients that may be at risk for anemia and in need
of further testing.
Comments on the study methods and design
There are several points to address regarding our re-
search design and methods. From a basic science per-
spective, these issues may be viewed as limitations.
However we see them as strengths because they repli-
cate clinical conditions of use. First, we accepted the first
SpHb value the device displayed in our study and did
not repeat the measurements to examine the data vari-
ance. We sought to use a clinical approach, where a rea-
sonable measurement and not the expected one is used.
Another strength is that we used the mode with a wider
range of acceptance for pulse wave abnormalities (so
called ‘maximal sensitivity’) thereby tolerating a larger
bias and SD. Using this mode would be the appropriate
setting for patients with cf-LVAD given that they lack
the needed pulsatile flow for the device to function. We
saw that enhancing the sensitivity would enable the de-
vice to detect the almost negligible pulse waves gener-
ated by these patients. Obtained LOA were even higher
than they should be for the FDA approval (2 g/dl).
Lastly, due to our clinical aim, a typical clinical scenario
was selected for this practical test.
While we see many of the above mentioned aspects of
this study as strengths, we realize there are limitations.
First, our study population of only 21 patients may have
influenced our limits of agreement, which might be
smaller by investigating larger sample sizes. Neverthe-
less, our data are in line with prior publications [11].
Second, blood samples were collected from the median
cubital vein and not from an arterial catheter from the
same hand as described in other publications [2,11].
However, we do not expect this to have a profound in-
fluence on our findings.
Conclusion
The Pronto-7W system could detect a SpHb value in all
patients with a cf-LVAD, despite their characteristic lack
of pulsatile flow. Accuracy of the device in the tested pa-
tient population was hampered by a wide range of limits
of agreement which make the Pronto-7W inappropriate
in patients with cf-LVAD presenting with anemia, how-
ever, this device might be sufficient as a screening
method used in routine exams for patients with cf-
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to case basis.
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